Table 2.
Response During and After Treatment
| Response | Genotype 2 (N = 23) | Genotype 3 (N = 24) | Total (N = 47) |
|---|---|---|---|
| HCV RNA < LLOQ during treatment, n/N (%) | |||
| At baseline | 0/23 | 0/24 | 0/47 |
| Week 1 | 10/23 (43) | 8/24 (33) | 18/47 (38) |
| Week 2 | 18/23 (78) | 16/23 (70) | 34/46 (74) |
| Week 4 | 22/22 (100) | 21/23 (91) | 43/45 (96) |
| Week 6 | 22/22 (100) | 22/23 (96) | 44/45 (98) |
| Week 8 | 22/22 (100) | 23/23 (100) | 45/45 (100) |
| Week 12 | 22/22 (100) | 22/22 (100) | 44/44 (100) |
| HCV RNA < LLOQ after end of treatment, n/N (%) | |||
| SVR4 | 22/23 (96) | 21/24 (88) | 43/47 (92) |
| 95% CI | [78-100] | [68-97] | [80-98] |
| SVR12 | 22/23 (96) | 20/24 (83) | 42/47 (89) |
| 95% CI | [78-100] | [63-95] | [77-97] |
| SVR 24 | 22/23 (96) | 20/24 (83) | 42/47 (89) |
| 95% CI | [78-100] | [63-95] | [77-97] |
| Overall virologic failure, n/N (%) | 0/23 | 2/24 (8) | 2/47 (4) |
| Relapse | 0/22 | 2/23 (9) | 2/45 (4) |
| Study drug completer | 0/22 | 2/22 (9) | 2/44 (5) |
| Study drug noncompleter | 0/0 | 0/1 | 0/1 |
| On-treatment virologic failure | 0/23 | 0/24 | 0/47 |
| Other | 1/23 (4) | 2/24 (8) | 3/47 (6) |
SVR, sustained virologic response; Other, subjects who did not achieve SVR12 and did not meet virologic failure criteria.